Nagendran Sukumar 4

What Happened
Nagendran Sukumar, President & Head of R&D and a director of Taysha Gene Therapies (TSHA), sold 200,000 shares in an open-market transaction on April 10, 2026 for a weighted average price of $4.46, generating approximately $892,000 in proceeds. On the same date he also exercised 19,021 stock-option shares at $1.71 per share, paying $32,526 to acquire those shares. The Form 4 also reports a related derivative conversion of 19,021 shares at $0 proceeds (see Key Details).

Key Details

• Transaction date: April 10, 2026 (reported on Form 4 filed April 13, 2026). Filing is within the Form 4 two-business-day deadline.
• Sale: 200,000 shares sold at a weighted average price of $4.46; total proceeds ≈ $892,000. Reported sale prices ranged from $4.335 to $4.625 per share (footnote F2).
• Exercise: 19,021 shares acquired via option exercise at $1.71/share; total cash paid $32,526.
• Derivative conversion: A separate line reports conversion/derivative entry for 19,021 shares with $0 proceeds (reported as derivative activity in the filing).
• Plan/authorization: The 200,000-share sale was executed pursuant to a Rule 10b5-1 trading plan adopted June 11, 2025 (footnote F1).
• Vesting note: The underlying option(s) vest 25% on Jan 2, 2025, then monthly over 36 months (footnote F3).
• Shares owned after transaction: Not disclosed in the provided filing excerpt.

Context
The activity combines an option exercise (insider paid $1.71/share to acquire 19,021 shares) and a separate open-market sale under a pre-established 10b5-1 plan. Sales under a 10b5-1 plan are typically scheduled trades and do not, by themselves, indicate the insider’s current sentiment about the company. The derivative line with $0 proceeds reflects conversion/exercise reporting on the Form 4 and is not cash received.